menu search

Skye bioscience receives us fda authorization of investigational new drug application for sbi-100 oe

Skye Bioscience Inc (OTCQB:SKYE) said the US Food and Drug Administration (FDA) has authorized it to proceed with the Investigational New Drug (IND) ...

December 20, 2022, 7:53 am

Madrigal pharmaceuticals shares soar on positive trial results for its nash and liver fibrosis drug resmetirom

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares have soared more than 250% after the biopharmaceutical company shared positive topline results from ...

December 19, 2022, 10:41 am

Viking therapeutics' stock rallies after madrigal shares positive data about its liver drug

Shares of Viking Therapeutics Inc. VKTX, +4.42% jumped 55% in premarket trading on Monday after a company that is also developing a selective thyroid ...

December 19, 2022, 8:42 am

Poolbeg pharma targets first half of next year for first trial of oral diabetes/anti-obesity drug

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has exclusively licensed specialist microencapsulation or nanoencapsulation developed by a company...

December 14, 2022, 2:40 am

Pharvaris shares soar on positive top-line phase 2 data from rapide-1 study as it releases 3q results

Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagon...

December 8, 2022, 11:34 am

Context therapeutics reports encouraging preliminary phase 2 data for ona-xr in metastatic breast cancer

Context Therapeutics (NASDAQ:CNTX) has announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended-release (ONA-XR), the c...

December 8, 2022, 8:38 am

Algernon pharmaceuticals says ifenprodil granted orphan drug designation by us fda for treatment of ipf

Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Ifenp...

December 5, 2022, 7:57 am

Pop biotechnologies’ snap vaccine system safe and effective in a phase ii clinical trial for covid-19

Featured Image for POP Biotechnologies Featured Image for POP Biotechnologies BUFFALO, N.Y., Nov. 30, 2022 (GLOBE NEWSWIRE) — POP Biotechnologies (P...

November 30, 2022, 8:01 pm

Astrazeneca (azn) boosts cell therapies with neogene deal

The acquisition of Neogene is set to give AstraZeneca (AZN) access to the latter's next-generation T-cell rece...

November 30, 2022, 9:47 am

Astrazeneca adds focus on personalised cancer cell therapy with us$320mln acquisition

AstraZeneca PLC (LSE:AZN) will spend up to US$320mln to strengthen its cancer business with an acquisition specialising in an innovative cell therapy ...

November 29, 2022, 3:35 am

Legend biotech set for clinical development of potential treatment for small cell lung cancer after fda approval

Legend Biotech Corporation (NASDAQ:LEGN) told investors that the US regulator, the Food and Drug Administration (FDA), had green-lighted its investiga...

November 21, 2022, 10:08 am

Adicet bio to present at upcoming investor conferences

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing fir...

September 7, 2022, 4:10 pm

Adicet bio to present at upcoming investor conferences

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing fir...

August 1, 2022, 4:10 pm

Celyad oncology to announce first half 2022 financial results and host conference call

MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company fo...

July 28, 2022, 1:05 am

Celyad oncology to announce first half 2022 financial results and host conference call

MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD)...

July 28, 2022, 1:00 am

Cytomx's breast cancer candidate meets primary goal of objective response rate

CytomX Therapeutics Inc's (NASDAQ: CTMX) Phase 2 study of praluzatamab ravtansine in hormone receptor-...

July 7, 2022, 6:32 am

Avalon globocare reveals new study using ai-powered protein design technology targeting glucose transporter against cancer

Avalon GloboCare Corp (NASDAQ:AVCO) announced a new study incorporating artificial intelligence (AI)-enhanced protein design technology that could acc...

June 30, 2022, 9:59 am

Immunogen: possible accelerated fda approval for ovarian cancer treatment

PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate rec...

June 20, 2022, 2:51 pm

Avalon globocare to team up with lu daopei hematology institute to develop companion diagnostics for car-t cancer treatments

Avalon GloboCare Corp (NASDAQ:AVCO) has signed a memorandum of understanding with Lu Daopei Hematology Institute (LDHI) to co-develop precision compan...

May 18, 2022, 10:53 am

Celyad oncology to present at the h.c. wainwright global investment conference

MONT-SAINT-GUIBERT, Belgium, May 17, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biote...

May 17, 2022, 4:05 pm


Search within

Pages Search Results: